Platelets, a type of blood cell that’s vital to clotting, can help stem the bleeding for trauma victims and even wounded soldiers on the battlefield. And one Cambridge, Mass.-based biotech company is working to make it easier to get the cells out to the front lines.

Platelet BioGenesis showed Thursday that it’s able to create 100 million platelets with one run of its bioreactor — a big step forward after 20 years of research and investments from funders as varied as the Department of Defense and an undergraduate investment club. Its founders presented the results in a poster at a Gordon Research Conference in Galveston, Texas.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy